Malaria Information and Prophylaxis, by Country [T]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Taiwan None Not Applicable Not Applicable Not Applicable
Tajikistan Rare indigenous cases. Chloroquine P. vivax 90%,

P. falciparum 10%

Mosquito avoidance only
Tanzania All areas at altitudes < 1,800 m (5,906 ft) Chloroquine P. falciparum >85%,

P. ovale >10%,

P. malariae, and P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Thailand Primarily in provinces that border Burma (Myanmar), Cambodia, and Laos, and the provinces of Kalasin, Krabi (Plai Phraya district), Nakhon Si Thammarat, Narathiwat, Pattani, Phang Nga (including Phang Nga City), Rayong, Sakon Nakhon, Songkhla, Surat Thani, and Yala, especially the rural forest and forest fringe areas of these provinces. Rare to few cases in other parts of Thailand, including other parts of Krabi Province and the cities of Bangkok, Chang Mai, Chang Rai, Koh Phangan, Koh Samui, and Phuket. None in the islands of Krabi Province (Koh Phi Phi, Koh Yao Noi, Koh Yao Yai, and Ko Lanta) and Pattaya City. Chloroquine and Mefloquine P. falciparum 50% (up to 75% some areas),

P. vivax 50% (up to 60% some areas),

P. ovale and P. knowlesi rare.

Provinces that border Burma (Myanmar), Cambodia, and Laos, the provinces of Kalasin, Plai Phraya district of Krabi, Nakhon Si Thammarat, Narathiwat, Pattani, Phang Nga (including Phang Nga City), Rayong, Sakon Nakhon, Songkhla, Surat Thani, and Yala:

Atovaquone-proguanil doxycycline, or tafenoquine6.

All other areas of Thailand with malaria, including the cities of Bangkok, Chang Mai, Chang Rai, Koh Phangan, Koh Samui, and Phuket:

Mosquito avoidance only.

Timor-Leste (East Timor) Present in Oecusse District. Rare cases in other districts. Chloroquine P. falciparum 50%,

P. vivax 50%,

P. ovale <1%,

P. malariae <1%

Oecusse District: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6.

Other districts: Mosquito avoidance only.

Togo All Chloroquine P. falciparum 85%,

P. ovale 5-10%,

Remainder P. vivax

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Tokelau (New Zealand) None Not Applicable Not Applicable Not Applicable
Tonga None Not Applicable Not Applicable Not Applicable
Trinidad and Tobago None Not Applicable Not Applicable Not Applicable
Tunisia None Not Applicable Not Applicable Not Applicable
Turkey None Not Applicable Not Applicable Not Applicable
Turkmenistan None Not Applicable Not Applicable Not Applicable
Turks and Caicos Islands (U.K.) None Not Applicable Not Applicable Not Applicable
Tuvalu None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: March 27, 2019